Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression

Anti-Cancer Drugs

Volumn 26, Issue 6, 2015, Pages 632-640

  Hang, Qun ^a,b   Sun, Ruochuan ^a   Jiang, Congqiao ^b   Li, Yongxiang ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BENGBU MEDICAL COLLEGE   (China)

Author keywords

apoptosis; lncRNA AK022798; multidrug resistance associated protein; multiple drug resistance; Notch 1; P glycoprotein

Indexed keywords

CISPLATIN; LONG UNTRANSLATED RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; NOTCH1 RECEPTOR; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; NOTCH1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH CANCER; UPREGULATION; CELL PROLIFERATION; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; RECEPTOR, NOTCH1; RNA, LONG NONCODING; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84930680087     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000227     Document Type: Article

References (28)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56:1-9.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
3. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241:27-39.
4. Wu A, Ji J. The 7th National Gastric Cancer Academic Conference: focus on translational research in gastric cancer. Chin J Cancer Res 2012; 24:408.
5. Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, et al. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol 2014; 35:1287-1295.
6. Ying L, Zu-An Z, Qing-Hua L, Qing-Yan K, Lei L, Tao C, Yong-Ping W. RAD001 can reverse drug resistance of SGC7901/DDP cells. Tumour Biol 2014; 35:9171-9177.
7. Hu J, Fang Y, Cao Y, Qin R, Chen Q. miR-449a regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci 2014; 59:336-345.
8. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006; 107:2223-2233.
9. South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 2012; 4:458-464.
10. Koduru S, Kumar R, Srinivasan S, Evers MB, Damodaran C. Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther 2010; 9:202-210.
11. Piazzi G, Fini L, Selgrad M, Garcia M, Daoud Y, Wex T, et al. Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget 2011; 2:1291-1301.
12. Yeh TS, Wu CW, Hsu KW, Liao WJ, Yang MC, Li AF, et al. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res 2009; 69:5039-5048.
13. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov 2011; 1:391-407.
14. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet 2010; 19 (R2):R152-R161.
15. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011; 29:742-749.
16. Zhang H, Wang X, Xu J, Sun Y. Notch1 activation is a poor prognostic factor in patients with gastric cancer. Br J Cancer 2014; 110:2283-2290.
17. Bolós V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007; 28:339-363.
18. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009; 16:633-647.
19. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137:216-233.
20. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284:770-776.
21. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, Pieper RO. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 2007; 106:417-427.
22. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. Highlevel coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005; 65:8530-8537.
23. Reedijk M, Odorcic S, Zhang H, Chetty R, Tennert C, Dickson BC, et al. Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol 2008; 33:1223-1229.
24. Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 2012; 31:4577-4587.
25. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011; 10: : 38-38.
26. Tsai MC, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 2011; 71:3-7.
27. Gupta RA, Shah N,Wang KC, Kim J, Horlings HM,Wong DJ, et al. Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464:1071-1076.
28. Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 2012; 29:1810-1816.